307 related articles for article (PubMed ID: 15015608)
1. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody.
Tokunaga Y; Nakagami M; Tokuka A; Ohsumi K
Anticancer Res; 2003; 23(2C):1763-8. PubMed ID: 12820455
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Takahashi K; Saito T
Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
[TBL] [Abstract][Full Text] [Related]
6. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):531-6. PubMed ID: 15309506
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
8. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
[TBL] [Abstract][Full Text] [Related]
9. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Sasaki H; Saito T
Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
[TBL] [Abstract][Full Text] [Related]
10. DPD activity and immunohistochemical DPD expression in human breast cancer.
Horiguchi J; Yoshida T; Koibuchi Y; Iijima K; Ninomiya J; Takei H; Yokoe T; Iino Y; Morishita Y
Oncol Rep; 2004 Jan; 11(1):65-72. PubMed ID: 14654904
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
Huang CL; Yokomise H; Kobayashi S; Fukushima M; Hitomi S; Wada H
Int J Oncol; 2000 Jul; 17(1):47-54. PubMed ID: 10853017
[TBL] [Abstract][Full Text] [Related]
12. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.
Nakayama Y; Inoue Y; Nagashima N; Katsuki T; Matsumoto K; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
Anticancer Res; 2005; 25(6A):3755-61. PubMed ID: 16302736
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
14. The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer.
Hotta T; Takifuji K; Taniguchi K; Sahara M; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Oncol Rep; 2006 Jul; 16(1):177-82. PubMed ID: 16786143
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Ishida H; Takeuchi I; Ohsawa T; Nakada H; Ishizuka N; Yokoyama M; Inokuma S; Suzuki T; Yamada H; Odaka A; Hoshino T; Murata N; Hashimoto D; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2267-70. PubMed ID: 12484051
[TBL] [Abstract][Full Text] [Related]
16. Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Mukai M; Sato S; Ninomiya H; Wakui K; Komatsu N; Tsuchiya K; Nakasaki H; Makuuchi H
Oncol Rep; 2005 Nov; 14(5):1165-9. PubMed ID: 16211280
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y
Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
19. [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
Xiao JX; Han M; Li L; Zhu J; Chen LH; Bai PS
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2136-9. PubMed ID: 16313827
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
